Enleofen is a Singapore-based biotechnology company focused on developing therapies that target the interleukin-11 (IL-11) signaling pathway to address fibrotic and inflammatory diseases.
The company advances monoclonal antibodies and related biologics aimed at modulating fibrosis in organs such as the lung, liver, and heart, and collaborates with industry partners to progress its candidates toward clinical development.
None yet. When a new project in the record names Enleofen as owner, partner or investor, it shows here.
BI 765423, targeting IL-11, enters Phase IIa trials for IPF, aiming to improve lung function. Pre-clinical studies show promise in halting fibrosis and restoring lung functionality.
